Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H26N5O8.Gd |
Molecular Weight | 573.66 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O
InChI
InChIKey=HZHFFEYYPYZMNU-UHFFFAOYSA-K
InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H26N5O8 |
Molecular Weight | 416.4063 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=1802131
Curator's Comment: Gadodiamide was developed by Salutar (Sunnyvale, Calif).
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | OMNISCAN Approved UseDiagnostic magnetic resonance imaging (MRI) indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues; facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space. Launch Date1993 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77.8 min |
0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GADODIAMIDE unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GADODIAMIDE unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201277Orig1s000PharmR.pdf#page=53 Page: 53.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. | 1998 Sep |
|
Gadolinium arteriography complicated by acute pancreatitis and acute renal failure. | 2001 Mar |
|
Gadodiamide-associated nephrogenic systemic fibrosis. | 2007 Jun |
|
Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. | 2007 Oct 1 |
|
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. | 2008 Apr |
|
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. | 2008 May |
|
NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. | 2010 Nov |
|
The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. | 2011 Jan |
|
Semi-quantification of endolymphatic size on MR imaging after intravenous injection of single-dose gadodiamide: comparison between two types of processing strategies. | 2013 Dec 25 |
|
The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. | 2015 Jul |
|
Intrathecal gadodiamide for identifying subarachnoid and ventricular neurocysticercosis. | 2015 Jul |
|
IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. | 2015 Sep |
|
T1 Signal-Intensity Increase in the Dentate Nucleus after Multiple Exposures to Gadodiamide: Intraindividual Comparison between 2 Commonly Used Sequences. | 2016 Aug |
|
Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide. | 2016 Jul 11 |
|
Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice. | 2016 Nov |
|
Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. | 2016 Nov |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:54:01 GMT 2023
by
admin
on
Fri Dec 15 15:54:01 GMT 2023
|
Record UNII |
84F6U3J2R6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
268408
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
NCI_THESAURUS |
C62358
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
WHO-VATC |
QV08CA03
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
NDF-RT |
N0000180184
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
NDF-RT |
N0000175862
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
WHO-ATC |
V08CA03
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/08/583
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65795
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
84F6U3J2R6
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
SUB126939
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
GADODIAMIDE
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
C064925
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
84F6U3J2R6
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
1287507
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
CC-17
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
41144
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
131410-48-5
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
4494
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
100000085190
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
m5624
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
153921
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
Gadodiamide
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
31642
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200346
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
7547
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
DTXSID201019701
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
SUB07862MIG
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
6636
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY | |||
|
DB00225
Created by
admin on Fri Dec 15 15:54:01 GMT 2023 , Edited by admin on Fri Dec 15 15:54:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
BASIS OF STRENGTH->SUBSTANCE |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |